USF-LVHN SELECT

Cutaneous Immune-Related Adverse Events Associated With Immunotherapy in Patients With Melanoma.

Publication/Presentation Date

5-1-2025

Abstract

BACKGROUND: Cutaneous immune-related adverse events (irCAEs) have been commonly reported as a consequence of immune checkpoint inhibitors (ICIs) for the treatment of advanced stage III and stage IV melanoma.

OBJECTIVE AND METHODS: We sought to compare systemic irAEs in melanoma patients taking ICIs, with and without irCAEs in a retrospective cohort study of 147 patients at Moffitt Cancer Center.

RESULTS: 38.8% of patients experienced an irCAE on adjuvant ICI therapy, and 54.4% of these patients also experienced a systemic irAE. There was no significant association between irCAEs and systemic irAEs in the adjuvant treatment group (P=0.240). Among patients who progressed on first-line ICI therapy, 28.8% of patients experienced an irCAE on second-line ICI therapy. Of these patients, 53.3% also experienced a systemic irAE. There was a significant association between irCAEs and systemic irAE in the metastatic treatment group (P< 0.001). The median overall survival for patients who encountered an irCAE was 118 months, compared to 69 months for those who did not experience an irCAE (P=0.102).

CONCLUSION: Patients with stage III and stage IV melanoma who progress on first-line ICI therapy and experience an irCAE are more likely to also experience a systemic irAE.

CITATION: Aflatooni S, Pinero-Crespo G, Kahlon S, et al. Cutaneous immune-related adverse events associated with immunotherapy in patients with melanoma. J Drugs Dermatol. 2025;24(5):490-493. doi:10.36849/JDD.8553.

Volume

24

Issue

5

First Page

490

Last Page

493

ISSN

1545-9616

Disciplines

Medical Education | Medicine and Health Sciences

PubMedID

40327569

Department(s)

USF-LVHN SELECT Program, USF-LVHN SELECT Program Students

Document Type

Article

Link to Full Text

Share

COinS